Redeye comments on Carasent’s Q1 2026 report, which showed solid ARR growth marginally above our forecast but net sales and earnings below expectations, driven by a weak consulting quarter and higher-than-expected OPEX. We maintain our positive view of Carasent, where organic ARR growth is the most important metric, although we are likely to cut EBITDA-CAPEX somewhat.
LÄS MER
